Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04246541 · ClinicalTrials.gov registry record · Phase 3

Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

A Phase 3 study, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
Phase 3
Development phase
48
Enrollment target

NCT04246541 is a Phase 3 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04246541, a Phase 3 study, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
48 participants
Enrollment target

Study Summary

The utilization of arthroscopic surgery to treat meniscus injuries has continued to increase in recent years, partly due to a younger, more active population, and improved technology and technique. However, pain management in the post-operative period is critical to the ability to perform this procedure as an outpatient surgery. Traditionally, oral narcotic agents have been the preferred analgesic postoperatively in orthopaedic surgery. However, these agents are associated with several side effects, including nausea/vomiting, constipation, and somnolence. In addition, opioid agents have a significant potential for abuse in comparison to non-narcotic analgesics. In light of the rising opioid epidemic and nationwide initiatives to limit narcotic usage, surgeons must explore alternate pain modalities in the acute postoperative period. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties.1 Multiple prior studies have examined the beneficial effect of oral and intravenous (IV) ketorolac as an analgesic in the postoperative period,1-3 including arthroscopic meniscus surgery. However, the beneficial effects of this agent following arthroscopic meniscus surgery have not been extensively described.

Interventions

  • DRUG Ketorolac
  • DRUG Oxycodone-Acetaminophen

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2019-04-23
Est. Completion 2021-09-12
Phase Phase 3

What the Registry Record Tells You About NCT04246541

The ClinicalTrials.gov registry entry for NCT04246541 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ketorolac is the first listed.

NCT04246541 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04246541 about?

NCT04246541 is a clinical study titled "Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery". The utilization of arthroscopic surgery to treat meniscus injuries has continued to increase in recent years, partly due to a younger, more active population, and improved technology and technique. However, pain management in the post-operative period is critical to the ability to perform this proce...

What is the current status of trial NCT04246541?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2019-04-23. Estimated completion is 2021-09-12.

What interventions are being tested in trial NCT04246541?

The interventions under investigation include: Ketorolac (DRUG), Oxycodone-Acetaminophen (DRUG).

Who is sponsoring clinical trial NCT04246541?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.